Loading
The trial that added Hengrui's PD-L1 antibody adebrelimab to chemotherapy for small cell lung cancer, with one of the larger survival gains seen in that disease.
462 patients, double blind. Median overall survival 15.3 versus 12.8 months (hazard ratio 0.72); two-year survival 31.3% versus 17.2%. NMPA approval March 2023. Together with ASTRUM-005 (serplulimab) it shows Chinese PD-(L)1 antibodies matching or exceeding the IMpower133 and CASPIAN benchmarks in a Chinese population.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Jiangsu Hengrui Pharmaceuticals, Carboplatin, Immune checkpoint inhibitors and the tag china.
Shares Jiangsu Hengrui Pharmaceuticals and the tag china.
Shares Jiangsu Hengrui Pharmaceuticals and the tag china.
Shares Ying Cheng, Small-cell lung cancer and the tag china.
Shares Jiangsu Hengrui Pharmaceuticals and the tag china.
Shares ASTRUM-005, Small-cell lung cancer and the tag china.
Shares Immune checkpoint inhibitors and the tag china.
Shares Immune checkpoint inhibitors and the tag china.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/